Clinical trials
Completed Triple Negative Breast Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
296 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2007 | 3 |
| 2008 | 7 |
| 2009 | 9 |
| 2010 | 16 |
| 2011 | 15 |
| 2012 | 13 |
| 2013 | 13 |
| 2014 | 17 |
| 2015 | 18 |
| 2016 | 32 |
| 2017 | 41 |
| 2018 | 31 |
| 2019 | 23 |
| 2020 | 16 |
| 2021 | 19 |
| 2022 | 9 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 296 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 17 |
| Novartis Pharmaceuticals | 9 |
| AstraZeneca | 8 |
| Hoffmann-La Roche | 8 |
| M.D. Anderson Cancer Center | 8 |
| Merck Sharp & Dohme LLC | 8 |
| Fudan University | 7 |
| City of Hope Medical Center | 5 |
| Mayo Clinic | 4 |
| MedSIR | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Triple Negative Breast Neoplasms | 296 |
| Breast Neoplasms | 137 |
| Carcinoma, Non-Small-Cell Lung | 49 |
| Ovarian Neoplasms | 41 |
| Neoplasms | 27 |
| Pancreatic Neoplasms | 26 |
| Neoplasm Metastasis | 25 |
| Small Cell Lung Carcinoma | 25 |
| Carcinoma, Renal Cell | 24 |
| Melanoma | 23 |
Trials
Showing 1 to 25 of 296. Each trial links to its page on Pharma Observatory.
196 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.